Marta Martín-Richard

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Joan Maurel Santasusana · 3 shared papers, 2014–2018 · strength 0.15
   • Paper Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy … DOI 10.1007/s00280-018-3682-9↗
   • Paper [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. DOI 10.1016/j.medcli.2016.07.033↗
   • Paper A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unres… DOI 10.1371/journal.pone.0082209↗
2. Berta Laquente · 2 shared papers, 2018–2020 · strength 0.15
   • Paper Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine pra… DOI 10.1186/s12904-020-00610-4↗
   • Paper Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy … DOI 10.1007/s00280-018-3682-9↗
3. Laura Visa · 2 shared papers, 2018–2020 · strength 0.15
   • Paper Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine pra… DOI 10.1186/s12904-020-00610-4↗
   • Paper Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy … DOI 10.1007/s00280-018-3682-9↗
4. Àngels Ginés Gibert · 2 shared papers, 2016–2018 · strength 0.11
   • Paper Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy … DOI 10.1007/s00280-018-3682-9↗
   • Paper [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. DOI 10.1016/j.medcli.2016.07.033↗
5. Luis Sabater-Orti · 2 shared papers, 2016–2018 · strength 0.11
   • Paper Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy … DOI 10.1007/s00280-018-3682-9↗
   • Paper [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. DOI 10.1016/j.medcli.2016.07.033↗
6. Helena Verdaguer · 1 shared paper, 2020 · strength 0.09
   • Paper Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine pra… DOI 10.1186/s12904-020-00610-4↗
7. Adelaida Garcia-Velasco · 1 shared paper, 2020 · strength 0.09
   • Paper Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine pra… DOI 10.1186/s12904-020-00610-4↗
8. Carles Pericay Pijaume · 1 shared paper, 2020 · strength 0.09
   • Paper Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine pra… DOI 10.1186/s12904-020-00610-4↗
9. Teresa Mercade Macarulla · 1 shared paper, 2020 · strength 0.09
   • Paper Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine pra… DOI 10.1186/s12904-020-00610-4↗
10. Cristina Arqueros Núñez · 1 shared paper, 2017 · strength 0.06
    • Paper SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients. DOI 10.1007/s12032-017-0993-3↗
11. David Páez · 1 shared paper, 2017 · strength 0.06
    • Paper SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients. DOI 10.1007/s12032-017-0993-3↗
12. Laureano Fernández‐Cruz · 1 shared paper, 2018 · strength 0.06
    • Paper Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy … DOI 10.1007/s00280-018-3682-9↗
13. Santiago Sánchez-Cabús · 1 shared paper, 2018 · strength 0.06
    • Paper Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy … DOI 10.1007/s00280-018-3682-9↗
14. Javier Rodríguez Rodríguez · 1 shared paper, 2018 · strength 0.06
    • Paper Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy … DOI 10.1007/s00280-018-3682-9↗
15. Susana Roselló · 1 shared paper, 2018 · strength 0.06
    • Paper Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy … DOI 10.1007/s00280-018-3682-9↗
16. Glòria Fernández‐Esparrach · 1 shared paper, 2016 · strength 0.05
    • Paper [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. DOI 10.1016/j.medcli.2016.07.033↗
17. Eva Cristina Vaquero · 1 shared paper, 2016 · strength 0.05
    • Paper [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. DOI 10.1016/j.medcli.2016.07.033↗
18. Fernando Rivera Herrero · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
19. Joaquina Martínez-Galán · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
20. José Luis Manzano Mozo · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
21. Manuel Benavides · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
22. Ruth Vera · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
23. Roberto Pazo-Cid · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
24. Javier Gallego-Plazas · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗
25. Carmen Guillén‐Ponce · 1 shared paper, 2017 · strength 0.05
    • Paper Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic… DOI 10.1016/j.ejca.2016.12.032↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.